Skip to content
中文EN

Cardiometabolic

GLP-1 and obesity, Lp(a), heart failure and arrhythmia — pivotal trials and industry shape.

260 picksRelatedClinical readoutsDeals & financingNucleic acid drugs

Latest picks

61–79 of 260
Oct 7Wed
  1. WeChat85

    Hengrui Oral GLP-1 Agonist HRS-7535 Beats Dapagliflozin on HbA1c in Phase 3 OUTSTAND-2

    HRS-7535, Hengrui Pharma's oral small-molecule GLP-1 receptor agonist, met non-inferiority versus dapagliflozin in the China phase 3 OUTSTAND-2 trial in type 2 diabetes patients inadequately controlled on metformin. HbA1c fell 1.50% to 1.68% across the 30 mg, 60 mg and 90 mg doses, versus 1.28% with dapagliflozin; the 90 mg dose was superior. Full methods are set for publication in Nature Medicine.

    Why it matters: Oral GLP-1 agonist shows non-inferiority and dose-dependent superiority over dapagliflozin in phase 3.

Oct 6Tue
  2. WeChat62

    SMOC-1 From Cardiomyocytes Protects Against Cardiac Rupture After Myocardial Infarction

    A study published online in Circulation on September 29, 2026, by teams from Beijing Anzhen Hospital and Thomas Jefferson University identifies cardiomyocyte-derived secreted modular calcium-binding protein-1 (SMOC-1) as an endogenous cardioprotective molecule. SMOC-1 promotes reparative scar formation and reduces the risk of cardiac rupture after acute myocardial infarction. The problem is large: autopsy data indicate cardiac rupture causes about 30% of early deaths after acute myocardial infarction, with in-hospital mortality of 70% to 90%.

    Why it matters: Points to a new endogenous target for preventing cardiac rupture, a highly lethal complication of acute myocardial infarction.

  3. YouTube55

    MedCram Explains Photometabolism: Infrared Photons May Modulate the Mitochondrial Electron Transport Chain

    MedCram's Roger Seheult presents the "photometabolism" hypothesis from the preprint "Metabolism in the solar photon field": infrared photons near 0.754 eV, in an atmospheric transparency window, penetrate skin and clothing and modulate the mitochondrial electron transport chain not by supplying chemical energy but by shifting electron-transfer barrier-crossing probabilities in a Marcus-framework sense of vibrational energy levels. The argument is scaled by incident solar power tracking body mass to the 3/4 power, matching basal metabolic rate scaling, and accommodates 2018 findings that 750/950 nm light reduces complex IV activity and oxygen consumption. The speakers stress correlation, not causation, and that the hypothesis awaits independent experimental validation.

    Why it matters: A cross-disciplinary preprint hypothesis reframes infrared light as a regulator of mitochondrial metabolism, with direct relevance to photobiomodulation research.

Oct 5Mon
  1. Nature54

    Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial

    Once-daily oral safiglipron, a small-molecule GLP-1RA, was non-inferior to dapagliflozin for HbA1c reduction at all tested doses and superior at 90 mg in adults with type 2 diabetes in a randomized, double-blind, active-comparator-controlled phase 3 trial. Safiglipron gave greater improvements in glycemic control, similar modest weight loss, and an acceptable safety profile. It offers an oral alternative in the GLP-1 receptor agonist class.

    Why it matters: Phase 3 data show an oral GLP-1RA matching and at 90 mg beating dapagliflozin on HbA1c.

  2. Reddit56

    The Lord of the Incretins: The Reign of Retatrutide... [Latest Research Update]

    Retatrutide, Eli Lilly's unapproved GLP-1/GIP/glucagon triple agonist, delivered mean weight reductions of 17.6%, 23.7% and 25.0% at 4, 9 and 12 mg once weekly versus 3.9% on placebo over 80 weeks in the 2,339-adult TRIUMPH phase 3 program, with a BLA planned for Q1 2027. Clinicians on r/doctorsUK flagged the real-world challenge of moving patients from unregulated gray-market vials, with injection-site infections and toxic reactions already reported, back to regulated supply once the drug is approved.

    Why it matters: Clinicians are publicly debating how to handle patients already self-sourcing retatrutide before approval.

  3. WeChat69

    Retatrutide achieves 20.8% weight loss at 80 weeks in TRIUMPH-2 topline results

    Retatrutide delivered an average weight loss of 20.8% at 80 weeks in the 12 mg group of the TRIUMPH-2 trial, which enrolled 1152 people with T2D across dose arms. A subgroup with baseline BMI of 35 or higher lost 23.4%. The topline results were published in The Lancet, and Eli Lilly plans to file with the FDA in Q1 2027.

    Why it matters: TRIUMPH-2 topline data show record weight loss with retatrutide in T2D, with an FDA filing planned.

Oct 4Sun
  1. WeChat59

    Novo Nordisk pays $300 million upfront for ex-China rights to Hengrui's GLP-1/GIP dual agonist HRS-1596

    Novo Nordisk has licensed HRS-1596, a GLP-1/GIP dual receptor agonist developed by Hengrui for weight loss and blood glucose control, gaining exclusive rights to develop, manufacture and commercialize it outside greater China. Hengrui receives an upfront payment of $300 million, with the deal worth up to $2.6 billion in total plus royalties on net sales. The drug has potential in obesity, type 2 diabetes and other metabolic diseases.

    Why it matters: Large-value licensing deal showing multinational pharma in-licensing Chinese GLP-1 pipeline assets.

  2. WeChat60

    Distinct brainstem circuits separate GLP-1 receptor agonist weight loss from aversion, J Clin Invest study shows

    Semaglutide and tirzepatide, both GLP-1 receptor agonists, suppress food intake but also cause nausea and aversive reactions. Prior work showed that neurons expressing GLP-1 receptors in two dorsal vagal complex nuclei, the nucleus of the solitary tract and the area postrema, both suppress food intake when activated, yet only area postrema activation causes aversion. The study from Weiwei Qiu and Martin G. Myers, Jr., published in J Clin Invest, identifies the key brainstem circuit underlying this dissociation.

    Why it matters: Separating weight-loss efficacy from aversive effects matters for optimizing GLP-1 receptor agonist therapy.

  3. WeChat34

    Lilly Reports Detailed Results from Phase 3 ACHIEVE-4 Trial of Oral GLP-1RA Orforglipron

    Eli Lilly has released detailed results from ACHIEVE-4, the phase 3 trial of the oral GLP-1 receptor agonist orforglipron. Diabetes is now the third most serious chronic disease threatening human health after cancer and cardiovascular and cerebrovascular disease. China has more than 140 million people with type 2 diabetes, and clinical care has shifted to integrated management of blood glucose, blood lipids, and cardiovascular risk.

    Why it matters: Three sources reported the same event

  4. WeChat60

    TAVI-First Strategy Noninferior to PCI-First in Severe Aortic Stenosis with Coronary Disease

    In severe aortic stenosis with coronary artery disease, performing TAVI before PCI was noninferior to PCI first for the one-year primary composite endpoint after randomization, the randomized TAVI PCI trial in NEJM shows; superiority was not established. All-cause death was 9.5% in both groups, and the TAVI-first group had lower rates of BARC type 3a bleeding. The trial, run across 29 high-volume German heart valve centers, is the first randomized comparison of the two staging orders when both procedures are planned.

    Why it matters: It is the first randomized trial to set the order of TAVI and PCI when both are planned.

Oct 3Sat
  1. WeChat43

    FDA Approves Edwards Lifesciences' Size-Adjustable AUTUS Pulmonary Valve for Children

    Edwards Lifesciences said on October 1, 2026 that the FDA has approved the AUTUS pulmonary valve, a size-adjustable valve designed for children with congenital heart disease that can expand as the child grows. Valve enlargement is done through minimally invasive transcatheter procedures, which may reduce the need for repeat open-chest surgeries that children traditionally face years after valve replacement.

    Why it matters: FDA approval of a first-of-kind growth-adaptable pediatric valve affects congenital heart disease practice.

  2. Medical Xpress50

    New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells

    CBL-514, an injectable that selectively induces apoptosis of fat cells, cut abdominal visceral adipose tissue volume by 12.01% from baseline four weeks after the last treatment in phase 2 participants (n=23), while placebo recipients (n=17) gained 5.68%, a 17.69 percentage-point difference. At later follow-up the between-group difference was 22.21 percentage points, and the drug was generally well tolerated with mostly mild injection-site reactions. Phase 3 trials for nonsurgical abdominal fat reduction are now recruiting.

    Why it matters: Phase 2 MRI data show an injectable fat-cell apoptosis drug reduces visceral fat, a target current obesity drugs do not directly address.

  3. WeChat47

    Nat Med | Phase 3 Trial of Oral Small-Molecule GLP-1 Receptor Agonist Safiglipron in Early Type 2 Diabetes Completed

    A phase 3 randomized controlled trial of safiglipron (HRS-7535), an oral small-molecule GLP-1 receptor agonist developed by Hengrui Pharma for early type 2 diabetes, was completed by the team of Xiao Xinhua and Ye Zi and published in Nature Medicine. Safiglipron is taken once daily by mouth, requires no injection, and has no fasting or food and water intake restrictions before or after dosing, potentially simplifying current GLP-1 receptor agonist treatment. The study evaluated its efficacy, safety, and metabolic effects as monotherapy.

    Why it matters: Three sources reported the same event

  4. WeChat51

    Chinese Oral Weight-Loss Drug Out-Licensed in Deal Worth Up to $2.6 Billion

    An oral weight-loss drug developed in China has been licensed to an overseas partner in a deal worth up to $2.6 billion in total. The agreement includes $300 million upfront plus payments tied to development, regulatory and commercial milestones, and the licensor is also eligible for sales royalties. The parties and drug name were not disclosed in the material.

    Why it matters: Large out-licensing deal for a Chinese oral weight-loss drug with a $300 million upfront payment.

  5. WeChat61

    Zealand Pharma petrelintide shows 10.7% weight loss at 42 weeks as three Phase III trials begin

    Zealand Pharma published ZUPREME-1 data for its amylin analogue petrelintide in The Lancet Diabetes and Endocrinology on September 30, with a simultaneous oral presentation at the 62nd EASD annual meeting. The once-weekly subcutaneous injection achieved up to 10.7% weight loss at 42 weeks as monotherapy, with gastrointestinal side effects close to placebo levels. Three global Phase III registration studies were launched eight days earlier.

    Why it matters: Competitive weight-loss data with placebo-level GI tolerability positions petrelintide against GLP-1s as registration trials begin.

  6. Reddit78

    NEW RETATRUTIDE DATA: 12 mg barely beat 9 mg, and more people quit on 9 mg than 12 mg. What's going on?

    A community post summarizes Lilly's phase 3 TRIUMPH-2 data for retatrutide: 1,152 patients with type 2 diabetes and obesity received 4/9/12 mg for 80 weeks, with mean weight loss of 12.7%/19.1%/20.8%.

    Why it matters: The post compares weight loss and dropout rates by dose, showing 12 mg added under 2 points over 9 mg with more dysesthesia.

Oct 2Fri
  1. BioSpace64

    Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS

    The GLP-1/GIP dual receptor agonist ribupatide, a weekly injectable from Kailera Therapeutics and Hengrui Pharma, produced dose-dependent weight loss of 10%, 15.1% and 20.2% at 1 mg, 2 mg and 4 mg in a Phase 2 trial of 158 Chinese women aged 18 to 40 with polyendocrine metabolic ovarian syndrome and obesity or overweight, versus 2.6% on placebo at 32 weeks. All ribupatide dose groups also showed increased menstrual frequency, while placebo cycles grew more infrequent, with no serious adverse events or discontinuations. The data suggest an incretin therapy could be developed specifically for PMOS, a condition where semaglutide and tirzepatide are used off-label without indication.

    Why it matters: First dedicated Phase 2 evidence that an incretin benefits PMOS beyond weight loss, in a condition lacking approved drug options.

  2. Reddit68

    Anyone else starting to pay attention to Eloralintide?

    A Reddit thread on r/GLP1ResearchTalk debates Eli Lilly's investigational amylin peptide Eloralintide, with some users reporting appetite suppression when pairing it with Zepbound (tirzepatide) in Lilly studies and others wary of grey-market sourcing and limited data. The discussion follows Lilly's Phase IIb topline (NCT06603571, 367 participants), in which the highest-dose combination achieved 23.3% weight loss (54.1 lb), presented at EASD on 30 September 2026, with Phase III planned for Q4 2026.

    Why it matters: Community use of an unapproved amylin candidate ahead of Phase III signals demand for GLP-1 combination obesity therapies.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org